Navigation Links
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
Date:2/27/2009

ult in chronic airway inflammation(4) and progressive loss of lung function, making it difficult to breathe normally.(4,6)

The FDA approval is based on two pivotal (Phase III) efficacy and safety trials, SHINE and SUN, which evaluated more than 3,600 patients ages 40 years and older with moderate to very severe COPD. (2) These studies demonstrated that patients using SYMBICORT pMDI 160/4.5 mcg had significantly greater mean improvements from baseline in pre-dose forced expiratory volume in one second (FEV1) averaged over the treatment period compared with formoterol 4.5 mcg and placebo.(2)

In addition, patients using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo.(2) Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was five minutes.(1)

SYMBICORT was generally well-tolerated over the 12-month study,(2) and the incidence of pneumonia was no different for SYMBICORT compared to placebo.(2) There was a higher incidence of potential lung infections other than pneumonia (e.g., bronchitis and viral lower respiratory tract infections) in patients receiving SYMBICORT 160/4.5 mcg than in those receiving formoterol 4.5 mcg or placebo.(2) The most common drug-related adverse events reported were nasopharyngitis (the common cold), oral candidiasis, bronchitis, sinusitis and viral upper respiratory tract infection.(2)

"Through these pivotal studies, SYMBICORT demonstrated rapid and sustained improvements in lung function and was generally well-tolerated long-term for patients with moderate to severe COPD,"(2) said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "Healthcare professionals and patients with severe COPD can now consider using SYMBI
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
2. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
3. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
4. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
5. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
6. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
7. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
8. Monsanto Board Approves 10 Percent Dividend Increase
9. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
10. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
11. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... Feb. 5 Genta,Incorporated (Nasdaq: GNTA ) announced ... Raymond P. Warrell, Jr., will provide a,company overview and ... Conference. The presentation is scheduled for Wednesday, February,13th at ... York, NY., About Genta, Genta Incorporated is ...
... LOUISVILLE, Colo., Feb. 5 Replidyne, Inc.,(Nasdaq: RDYN ... on,Tuesday, February 26, 2008 at 4:45 P.M. ET to report ... an upcoming,investor conference in February 2008., Earnings conference ... Collins, President and CEO, and other members of Replidyne,s ...
... Therapeutics,Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals ... Mooney, M.D, Chairman,and Chief Executive Officer, will present ... 2008 at 3:50 pm Mountain Standard Time (5:50 ... at the Four Seasons,Resort in Scottsdale, Arizona. A ...
Other Biology Technology:Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 2Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 3Echo Therapeutics to Present at RedChip Small-Cap Investor Conference 2
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... known laboratory studies that explores memory deficits associated with ... Clinic researchers have evidence that this infection can lead ... was conducted in animal models, suggests that over the ... have a permanent effect on memory late in life. ...
... the first large, single-institution series directly comparing weight-loss ... of Chicago found that a newer operation, the ... the standard operation, the Roux-en-Y gastric bypass. , ... Surgery, the researchers report that the duodenal switch ...
... loss due to the toxic effects of chemotherapy might one ... and gene therapy, thanks to work done with mouse models ... of genetic mutations that disrupt different parts of the ear ... as well as hearing loss caused by long-term exposure to ...
Other Biology News:Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits 2Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits 3For super-obese patients, duodenal switch beats gastric bypass 2For super-obese patients, duodenal switch beats gastric bypass 3St. Jude finds clues to hearing loss from chemotherapy 2
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
...
Medium for cryopreserving subcutaneous or omental preadipocytes...
Biology Products: